GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
2019-09-24 $0.350 $0.370 $0.337 $0.338 776 284
2019-09-23 $0.342 $0.348 $0.338 $0.345 240 252
2019-09-20 $0.371 $0.375 $0.340 $0.341 527 181
2019-09-19 $0.378 $0.380 $0.362 $0.365 194 471
2019-09-18 $0.375 $0.380 $0.360 $0.380 408 890
2019-09-17 $0.390 $0.395 $0.356 $0.367 621 677
2019-09-16 $0.388 $0.400 $0.372 $0.386 612 806
2019-09-13 $0.370 $0.390 $0.353 $0.385 1 071 775
2019-09-12 $0.420 $0.420 $0.365 $0.370 1 997 338
2019-09-11 $0.360 $0.437 $0.342 $0.416 5 064 184
2019-09-10 $0.333 $0.363 $0.330 $0.359 963 058
2019-09-09 $0.340 $0.347 $0.320 $0.337 1 065 362
2019-09-06 $0.339 $0.347 $0.332 $0.334 889 558
2019-09-05 $0.330 $0.350 $0.320 $0.335 1 324 834
2019-09-04 $0.318 $0.330 $0.311 $0.328 526 729
2019-09-03 $0.335 $0.337 $0.306 $0.315 1 067 310
2019-08-30 $0.317 $0.356 $0.305 $0.342 2 553 370
2019-08-29 $0.320 $0.320 $0.306 $0.310 264 966
2019-08-28 $0.300 $0.330 $0.293 $0.320 919 995
2019-08-27 $0.290 $0.310 $0.290 $0.308 227 881
2019-08-26 $0.300 $0.310 $0.290 $0.310 207 434
2019-08-23 $0.309 $0.312 $0.300 $0.300 140 385
2019-08-22 $0.310 $0.318 $0.307 $0.309 144 526
2019-08-21 $0.325 $0.325 $0.310 $0.314 193 931
2019-08-20 $0.320 $0.330 $0.300 $0.319 328 684
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT